Imperial College London


Faculty of MedicineDepartment of Brain Sciences

Professor of Neurology and Genomic Medicine



m.johnson Website




E419Burlington DanesHammersmith Campus






BibTex format

author = {Srivastava, P and van, Eyll J and Godard, P and Manuela, M and Delahaye-Duriez, A and Van, Steenwinckel J and Gressens, P and Danis, B and Vandenplas, C and Patrik, F and Leclercq, K and Mairet-Coello, G and Cardenas, A and Vanclef, F and Laaniste, L and Niespodziany, I and Keaney, J and Gasser, J and Gillet, G and Shkura, K and Chong, S-A and Behmoaras, J and Kadiu, I and Petretto, EG and Kaminski, R and Johnson, M},
doi = {10.1038/s41467-018-06008-4},
journal = {Nature Communications},
title = {A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target},
url = {},
volume = {9},
year = {2018}

RIS format (EndNote, RefMan)

AB - The identification of drug targets is highly challenging, particularly for diseases of the brain. To address this problem, we developed and experimentally validated a general computational framework for drug target discovery that combines gene regulatory information with causal reasoning (“Causal Reasoning Analytical Framework for Target discovery”—CRAFT). Using a systems genetics approach and starting from gene expression data from the target tissue, CRAFT provides a predictive framework for identifying cell membrane receptors with a direction-specified influence over disease-related gene expression profiles. As proof of concept, we applied CRAFT to epilepsy and predicted the tyrosine kinase receptor Csf1R as a potential therapeutic target. The predicted effect of Csf1R blockade in attenuating epilepsy seizures was validated in three pre-clinical models of epilepsy. These results highlight CRAFT as a systems-level framework for target discovery and suggest Csf1R blockade as a novel therapeutic strategy in epilepsy. CRAFT is applicable to disease settings other than epilepsy.
AU - Srivastava,P
AU - van,Eyll J
AU - Godard,P
AU - Manuela,M
AU - Delahaye-Duriez,A
AU - Van,Steenwinckel J
AU - Gressens,P
AU - Danis,B
AU - Vandenplas,C
AU - Patrik,F
AU - Leclercq,K
AU - Mairet-Coello,G
AU - Cardenas,A
AU - Vanclef,F
AU - Laaniste,L
AU - Niespodziany,I
AU - Keaney,J
AU - Gasser,J
AU - Gillet,G
AU - Shkura,K
AU - Chong,S-A
AU - Behmoaras,J
AU - Kadiu,I
AU - Petretto,EG
AU - Kaminski,R
AU - Johnson,M
DO - 10.1038/s41467-018-06008-4
PY - 2018///
SN - 2041-1723
TI - A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target
T2 - Nature Communications
UR -
UR -
VL - 9
ER -